SCHEMBL2565828

SCHEMBL2565828

COC(=O)c1onc(-c2ccccc2)c1C=O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 5/20 0.47
POLB P06746 2/20 0.46
GABRA5 P31644 3/20 0.42
LMNA P02545 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA3 P34903 1/20 0.42
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
CRHBP P24387 1/20 0.41
KMT2A Q03164 1/20 0.41
CRHR2 Q13324 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12000493 0.81 PTGS1 (0.60) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL2568217 0.81 PTGS1 (0.73) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL2570531 0.79 PTGS1 (0.67) PTGS1SMN1; SMN2ALDH1A1POLBLMNA
SCHEMBL17874015 0.79 PTGS1 (0.58) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL13349506 0.77 PTGS1 (0.56) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL13285212 0.77 PTGS1 (0.46) PTGS1SMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL2570798 0.77 PTGS1 (0.71) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL2565906 0.76 PTGS1 (0.55) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL2570844 0.76 PTGS1 (0.55) PTGS1SMN1; SMN2ALDH1A1POLBGABRA5
SCHEMBL2570361 0.76 PTGS1 (0.62) PTGS1SMN1; SMN2ALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
EP-2382212-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES Bristol-Myers Squibb Company (US) 2011-11-02 EP disclosed
WO-2010085581-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS S1PR4, S1PR3, S1PR1 PTGS1 1441/4885SMN1; SMN2 3484/4885ALDH1A1 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.